iTeos Therapeutics to Participate in Upcoming U.S. Conferences in August
06 août 2018 07h00 HE
|
iTeos Therapeutics SA
iTeos Therapeutics to Participate in Upcoming U.S. Conferences in August Gosselies, Belgium – August 6, 2018 – iTeos Therapeutics SA, a biotechnology company developing novel cancer immunotherapies,...
iTeos Therapeutics Appoints Scott Chappel as Chief Scientific Officer
03 juil. 2018 07h00 HE
|
iTeos Therapeutics SA
iTeos Therapeutics Appoints Scott Chappel as Chief Scientific Officer Gosselies, Belgium – July 3, 2018 – iTeos Therapeutics SA, a biotechnology company developing novel cancer immunotherapies, today...
iTeos Therapeutics Appoints Scott Chappel as Chief Scientific Officer
03 juil. 2018 01h00 HE
|
iTeos Therapeutics SA
iTeos Therapeutics Appoints Scott Chappel as Chief Scientific Officer Gosselies, Belgium – July 3, 2018 – iTeos Therapeutics SA, a biotechnology company developing novel cancer immunotherapies, today...
iTeos Therapeutics Expands Board of Directors with the Appointment of David Hallal as Chairman and Tim Van Hauwermeiren as an Independent Director
27 juin 2018 06h00 HE
|
iTeos Therapeutics SA
iTeos Therapeutics Expands Board of Directors with the Appointment of David Hallal as Chairman and Tim Van Hauwermeiren as an Independent Director Two new appointments follow oversubscribed $75...
iTeos Therapeutics Expands Board of Directors with the Appointment of David Hallal as Chairman and Tim Van Hauwermeiren as an Independent Director
27 juin 2018 01h00 HE
|
iTeos Therapeutics SA
iTeos Therapeutics Expands Board of Directors with the Appointment of David Hallal as Chairman and Tim Van Hauwermeiren as an Independent Director Two new appointments follow oversubscribed $75...
iTeos Therapeutics Completes $75 Million Series B Financing
20 juin 2018 07h00 HE
|
iTeos Therapeutics SA
iTeos Therapeutics Completes $75 Million Series B Financing Oversubscribed financing round led by new U.S. investor MPM Capital Proceeds to support accelerated development of innovative...
iTeos Therapeutics Completes $75 Million Series B Financing
20 juin 2018 01h00 HE
|
iTeos Therapeutics SA
iTeos Therapeutics Completes $75 Million Series B Financing Oversubscribed financing round led by new U.S. investor MPM Capital Proceeds to support accelerated development of innovative...
iTeos Therapeutics to Present Preclinical Data from A2A Receptor Antagonist and Anti-TIGIT Antibody Programs at AACR
12 avr. 2018 03h37 HE
|
iTeos Therapeutics SA
iTeos Therapeutics to Present Preclinical Data from A2A Receptor Antagonist and Anti-TIGIT Antibody Programs at AACR Gosselies, Belgium - April 12, 2018 - iTeos Therapeutics SA, a biotechnology...
iTeos Therapeutics to Present New Preclinical Data from A2A Receptor Antagonist and Anti-TIGIT Antibody Programs at Molecular Medicine Tri-Conference
09 févr. 2018 08h00 HE
|
iTeos Therapeutics SA
iTeos Therapeutics to Present New Preclinical Data from A2A Receptor Antagonist and Anti-TIGIT Antibody Programs at Molecular Medicine Tri-Conference Two Phase 1 trials to start in 2018 for A2A...
iTeos Therapeutics to Present New Preclinical Data from A2A Receptor Antagonist and Anti-TIGIT Antibody Programs at Molecular Medicine Tri-Conference
09 févr. 2018 02h01 HE
|
iTeos Therapeutics SA
iTeos Therapeutics to Present New Preclinical Data from A2A Receptor Antagonist and Anti-TIGIT Antibody Programs at Molecular Medicine Tri-Conference Two Phase 1 trials to start in 2018 for A2A...